SynbioTech Unveils Microbiome Platform for Women's Healthy Aging

KAOHSIUNG, TAIWAN – May 01, 2026 – As the conversation around women's health evolves from targeted treatments to comprehensive well-being, Taiwan-based SynbioTech is positioning itself at the forefront of this shift. The company announced it will unveil a new microbiome-based platform for women's healthy aging at the upcoming Vitafoods Europe 2026 conference in Barcelona.

This move signals a significant step for the biotechnology firm, known for its probiotic and postbiotic solutions. By focusing on the intersection of two booming markets—healthy aging and women's health—SynbioTech is tapping into a powerful consumer demand for products that support long-term vitality, strength, and independence. The global women's health market, valued at over $38 billion in 2024, is projected to exceed $51 billion by 2030, while the healthy aging supplement sector is also on a steep growth trajectory. SynbioTech aims to capture this opportunity by providing scientifically validated ingredients that address the interconnected nature of women's wellness as they age.

A New Paradigm: From Single Claims to Holistic Wellness

The concept of “anti-aging” is increasingly being replaced by a more empowering “healthy aging” philosophy, which prioritizes quality of life over simply combating visible signs of aging. This paradigm shift is particularly relevant in women's health, where the biological transitions of midlife, such as menopause, can impact everything from bone density and muscle mass to metabolic and gut health. Experts note that as estrogen levels decline, the gut microbiome often becomes a central command center influencing inflammation, metabolism, and even brain health.

Recognizing this, the industry is moving away from single-function products. A supplement for joint pain or a separate one for digestive issues no longer reflects how consumers, particularly aging women, view their health. Instead, they seek integrated solutions that acknowledge the body as a connected system. This is where microbiome science is making its most significant impact.

SynbioTech's new platform is a direct response to this trend. “Women's healthy aging is no longer defined by single-function products,” said Sean Yang, COO of SynbioTech, in a recent statement. “Our portfolio brings together probiotic and postbiotic solutions built around specific microbiome-related pathways, from strength and mobility to intimate wellness and metabolic balance.”

A Science-Backed Arsenal for Active Aging

The centerpiece of SynbioTech's showcase is TWK10®, a Lactiplantibacillus plantarum strain originally isolated from Taiwanese pickled cabbage. Initially celebrated in the sports nutrition world—winning the 2021 NutraIngredients-USA Award for Sports Nutrition Ingredient of the Year—TWK10® is now being positioned for the active aging market. Its relevance stems from a robust body of evidence, including 9 clinical studies and 27 publications, demonstrating its ability to support the very foundations of an active life.

Clinical trials have shown that TWK10® supplementation leads to a 3% increase in muscle mass, a 13% improvement in grip strength, and a 16.8% enhancement in mobility and agility. Furthermore, it has been shown to boost endurance by an impressive 51% and double the absorption of amino acids, which is critical for efficient protein utilization via the gut-muscle axis. For aging women concerned with sarcopenia (age-related muscle loss) and maintaining independence, these are powerful, tangible benefits. The strain's efficacy has been recognized with an official anti-fatigue health claim from Taiwan's FDA.

Beyond muscle health, the platform features a suite of specialized probiotic and postbiotic solutions targeting other key areas of women's aging:

• Gut & Digestive Health: ABKefir®, a symbiotic blend of seven kefir-derived strains, has been clinically shown to relieve common gastrointestinal issues like constipation, bloating, and abdominal pain.

• Intimate Wellness: SynForU® HerCare is a six-strain blend clinically proven to reduce symptoms of recurrent vaginal yeast infections by 44% and associated emotional stress by 36%, addressing a condition that affects an estimated 138 million women annually.

• Joint & Mobility Support: The postbiotic LDL557™ targets the gut-joint axis, with preclinical data showing it can reduce cartilage matrix loss by up to 80%, offering a next-generation approach to joint health.

• Metabolic & Renal Health: SynForU® ReMain and FS4722™ target the emerging gut-kidney and gut-liver-kidney axes. SynForU® ReMain has shown clinical evidence of improving kidney function markers, while FS4722™ shows preclinical promise in regulating uric acid metabolism.

Taiwan's Probiotic Powerhouse Goes Global

Established in 2000, SynbioTech has built a formidable reputation for scientific rigor. The company maintains a culture bank with over 2,000 bacterial strains and has secured over 60 patents and published more than 100 scientific papers. This deep commitment to R&D has resulted in numerous accolades, including multiple Gold Medals at the US Innovation Awards for its ingredients and a Vitafoods Europe Innovation Award in 2025 for TWK10®.

Operating in over 35 global markets and partnering with hundreds of brands, the company has a proven track record of translating complex science into market-ready solutions. A key part of its strategy involves strategic partnerships, such as the exclusive licensing agreement with Lonza for TWK10® in the competitive North American market.

By launching this comprehensive platform, SynbioTech is not just introducing new ingredients; it is providing brand partners with a scientifically validated foundation to create the next generation of women's wellness products. The company will highlight how its probiotic and postbiotic science can be incorporated into a variety of consumer-friendly formats, including capsules, powders, functional beverages, and gummies.

As the industry gathers in Barcelona for Vitafoods Europe 2026, all eyes will be on Booth 3G236. SynbioTech’s presentation represents more than just a product launch; it is a clear indicator of the future of women’s health—a future that is holistic, scientifically driven, and powered by the vast potential of the human microbiome.